ロード中...

CRISPR/Cas9 gene editing for curing sickle cell disease

Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic...

詳細記述

保存先:
書誌詳細
出版年:Transfus Apher Sci
主要な著者: Park, So Hyun, Bao, Gang
フォーマット: Artigo
言語:Inglês
出版事項: 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8049447/
https://ncbi.nlm.nih.gov/pubmed/33455878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.transci.2021.103060
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!